J&J's Janssen Pharma Seeks Razadyne Approval In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Janssen Pharmaceutical K.K., a Johnson & Johnson pharmaceutical subsidiary in Japan, applied for distribution and marketing approval for its Alzheimer's disease drug Razadyne (galantamine) with Japan's Ministry of Health, Labor and Welfare, in a market currently monopolized by Eisai's Aricept, a company spokesman said March 2